Caitlyn regularly counsels pharmaceutical, biotech, and medical device companies on a variety of regulatory, compliance, and enforcement issues that impact their sales, marketing, and pricing activities. Caitlyn has specific expertise and experience providing strategic advice on laws that regulate drug pricing decisions, federal and state initiatives focused on driving transparency into financial relationships between manufacturers and health care providers, and myriad laws and industry standards that govern and restrict how our clients interact with health care providers (e.g., gift bans, compliance program mandates, the PhRMA/AdvaMed Codes, sales representative licensing/registration requirements, federal and state government ethics laws, and lobbying laws). Caitlyn has substantial experience counseling clients on the Inflation Reduction Act's Medicare Drug Price Negotiation Program, including from initial drug selection through implementation of maximum fair price. 

Caitlyn also provides counsel to the Ad Hoc Sunshine and State Law Compliance Group (a coalition of pharmaceutical, biotechnology, and medical device manufacturers) on a variety of laws and regulations, including the federal Physician Payment Sunshine Act and related state laws, as well as state drug price transparency, prescription drug affordability board (PDAB), and price gouging laws.

Back to Page